BIological effects of a new vacuolar-H,+-ATPase inhibitor in colon carcinoma cell lines

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 606-616

  Supino, Rosanna ^a   Scovassi, A Ivana ^b   Croce, Anna Cleta ^b   Bo, Laura Dal ^a   Favini, Enrica ^a   Corbelli, Alessandro ^c   Farina, Carlo ^d   Misiano, Paola ^d   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Brane Discovery   (Italy)

Author keywords

Antiproliferative effect; Colon carcinoma; Lysosomes; V H ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ALPHAVBETA5 INTEGRIN; BAFILOMYCIN; NIK 12192; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG;

ANOIKIS; APOPTOSIS; CANCER CELL CULTURE; CELL ADHESION; CELL DEATH; CELL PH; CELL VACUOLE; CELLULAR DISTRIBUTION; COLON CARCINOMA; COLONY FORMING UNIT; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYSOSOME; MEMBRANE POTENTIAL;

EID: 69149104880     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04705.x     Document Type: Conference Paper

References (22)

1. Hinton, A., S. Bond M. Forgac. 2009. V-ATPase functions in normal and disease processes. Pflugers. Arch. 447 : 589 598.
2. Bowman, E.J. B.J. Bowman. 2005. V-ATPases as drug targets. J. Bioenerg. Biomembr. 37 : 431 435.
3. Sennoune, S.R., K. Bakunts, G.M. Martínez, et al. 2004. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am. J. Physiol. Cell Physiol. 286 : 1443 1452.
4. Martínez-Zaguilán, R., N. Raghunand, R.M. Lynch, et al. 1999. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem. Pharmacol. 57 : 1037 1046.
5. Luciani, F., M. Spada, A. De Milito, et al. 2004. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 96 : 1702 1713.
6. Petrangolini G., R. Supino, G. Pratesi, et al. 2006. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J. Pharmacol. Exp. Ther. 318 : 939 946.
7. Sennoune, S.R., D. Luo R. Martinez-Zaguilan. 2004. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem. Biophys. 40 : 185 206.
8. Farina, C., S. Gagliardi, G. Nadler, et al. 2001. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase. Farmaco 56 : 113 116.
9. Farina, C. S. Gagliardi. 2002. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr. Pharm. Des. 8 : 2033 2048.
10. Supino, R., G. Petrangolini, G. Pratesi, et al. 2008. Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. J. Pharmacol. Exp. Ther. 324 : 15 22.
11. Skehan, P., R. Storeng, D. Scudiero, et al. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 : 1107 1112.
12. Yamamoto, A., Y. Tagawa, T. Yoshimori, et al. 1998. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 23 : 33 42.
13. Chen, J., M.A. Skinner, W. Shi, et al. 2007. The 16 kDa subunit of vacuolar H+-ATPase is a novel sarcoglycan-interacting protein. Biochim. Biophys. Acta. 1772 : 570 579.
14. Lee, B.S., S.L. Gluck L.S. Holliday. 1999. Interaction between vacuolar H(+)-ATPase and microfilaments during osteoclast activation. J. Biol. Chem. 274 : 29164 29171.
15. Lee, I., M.A. Skinner, H.B. Guo, et al. 2004. Expression of the vacuolar H+-ATPase 16-kDa subunit results in the Triton X-100-insoluble aggregation of beta1 integrin and reduction of its cell surface expression. J. Biol. Chem. 279 : 53007 53014.
16. Hong, J., Y. Nakano, A. Yokomakura, et al. 2006. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells. J. Pharmacol. Exp. Ther. 319 : 672 681.
17. Nakashima, S., Y. Hiraku, S. Tada-Oikawa, et al. 2003. Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J. Biochem. 134 : 359 364.
18. Shacka, J.J., B.J. Klocke K.A. Roth. 2006. Autophagy, bafilomycin and cell death: the "a-B-cs" of plecomacrolide-induced neuroprotection. Autophagy 2 : 228 230.
19. Fernandes, F., L.M. Loura A. Fedorov, et al. 2006. Binding assays of inhibitors towards selected V-ATPase domains. Biochim. Biophys. Acta 1758 : 1777 1786.
20. Whyteside, G., P.J. Meek, S.K. Ball, et al. 2005. Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain. Biochemistry 44 : 15024 15031.
21. Visentin, L., R.A. Dodds, M. Valente, et al. 2000. A selective inhibitor of the osteoclastic V-H-(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J. Clin. Invest. 106 : 309 318.
22. Syrigos, K.N. A.J. Karayiannakis. 2006. Adhesion molecules as targets for the treatment of neoplastic diseases. Curr. Pharm. Des. 12 : 2849 2861.